Anti-CTLA-4 antibodies and methods of use thereof
US11013802B2 · kind B2 · utility
3Cited by
59References
21Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 7, 2017 |
| Grant date | May 25, 2021 |
| Priority date | — |
| Expiry date | Jul 16, 2039 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.